A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer

• Hauptverfasser: Hephzibah Rani S. Tagaram (VerfasserIn), Dhimant Desai (VerfasserIn), Guangfu Li (VerfasserIn), Dai Liu (VerfasserIn), C. Bart Rountree (VerfasserIn), Kavitha Gowda (VerfasserIn), Arthur Berg (VerfasserIn), Shantu Amin (VerfasserIn), Kevin F. Staveley-O'Carroll (VerfasserIn), Eric T. Kimchi (VerfasserIn)
• Format: Buch
• Veröffentlicht: MDPI AG, 2016-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Hepatocellular carcinoma (HCC) is the third most deadly cancer in the world. New treatment strategies are desperately needed due to limited standard therapies. Activation of the Erk, Akt, and STAT3pathways is implicated in the prognosis of HCC. The Se,Se'-1,4-phenylenebis(1,2-ethanediyl) bisiso...